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Abstract
Virus-like particles (VLPs) are formed by the self-assembly of envelope and/or capsid proteins from
many viruses. Some VLPs have been proven successful as vaccines, and others have recently found
applications as carriers for foreign antigens or as scaffolds in nanoparticle biotechnology. However,
production of VLP was usually impeded due to low water-solubility of recombinant virus capsid
proteins. Previous studies revealed that virus capsid and envelope proteins were often
posttranslationally modified by SUMO in vivo, leading into a hypothesis that SUMO modification
might be a common mechanism for virus proteins to retain water-solubility or prevent improper
self-aggregation before virus assembly. We then propose a simple approach to produce VLPs of
viruses, e.g., foot-and-mouth disease virus (FMDV). An improved SUMO fusion protein system we
developed recently was applied to the simultaneous expression of three capsid proteins of FMDV
in E. coli. The three SUMO fusion proteins formed a stable heterotrimeric complex. Proteolytic
removal of SUMO moieties from the ternary complexes resulted in VLPs with size and shape
resembling the authentic FMDV. The method described here can also apply to produce capsid/
envelope protein complexes or VLPs of other disease-causing viruses.
Background
Foot-and-mouth disease (FMD) is a severe, highly conta-
gious viral disease of cloven-hoofed animals, such as cat-
tle, pig, sheep, goats and deer, and is the most
economically devastating livestock disease in the world.
The 2001 outbreak in the UK caused stock losses of more
than 12 billion euros. Although animals can be protected
against FMD by vaccination with killed FMDV, prophylac-
tic vaccination is still impossible for several reasons. First,
the danger that vaccinated animals may become carriers
due to residual live virus in the vaccine would make it
impossible to maintain an international export trade in
meat and livestock. Second, at current prices, the cost of
prophylactic vaccination using the killed FMDV is too
high. Third, killed virus vaccines are not produced in
many FMD-free countries. Unfortunately, the risks of new
outbreaks are increasing due to globalization and the
increased possibility of bioterrorism. If it were introduced
into the United States, which is FMD-free, the disease
could cause 100 billions of dollars in losses to the U.S.
economy [1]. The development of a cheap and noninfec-
tious subunit or virus-like particle (VLP) vaccine for pro-
phylactic use is therefore a matter of world-wide interest.
VLPs consist of protein(s) derived from the capsid of a
virus. They are noninfectious because while they resemble
the virus from which they were derived, they lack the viral
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nucleic acids. VLPs used as vaccines are often very effective
at eliciting both T cell and B cell immune responses [2,3].
VLPs have also recently found application as as carriers for
foreign antigens [2,3] or scaffolds in nanoparticle biotech-
nology [4].
FMDV is a small RNA virus (27 nm in diameter) of the
Picornaviridae  family (see http://www.picornaviri
dae.com/). FMDV particles are composed of 60 copies of
each of four capsid proteins termed VP1, VP2, VP3 and
VP4, which are cleavage products of the P1 capsid precur-
sor polypeptide. During assembly, five protomers, each
containing one copy of VP0, VP1, and VP3, assemble into
a pentamer, and 12 pentamers associate with a newly
transcribed RNA molecule to form a virus particle. Cleav-
age of VP0 to VP2 and VP4, which is considered to be
autocatalytic, is normally observed only upon encapsida-
tion of RNA in mature virions [1]. Attempts have been
made to produce subunit vaccines by expressing FMDV
capsid protein(s) in E. coli. These recombinant capsid pro-
teins exhibited poor water solubility and were adminis-
tered in vaccine studies either in denatured forms [5-7] or
after a tedious refolding procedure [8]. To overcome this
technical bottleneck, we recently developed an improved
SUMO (Smt3) fusion protein system in E. coli to produce
several water-soluble virus capsid proteins, including
FMDV-VP3 [9]. Here, Smt3 serves not only as a solubility
enhancer but also as a protease recognition site. SUMO
proteases have the advantage of recognizing the tertiary
structure of Smt3, rather than a linear amino acid
sequence like other proteases commonly used in the
fusion protein approach [10].
Studies have revealed that the capsid and envelope pro-
teins of several viruses could either interact with SUMO or
Ubc9 (the SUMO E2 ligation enzyme) or were SUMO
modified during virus infection; these viruses including
the Tula hantavirus, Epstein-Barr virus, cyto-Megalo virus,
Dengue virus, herpes virus and Molony murine leukemia
virus [11-14]. Moreover, quantitative SUMO modification
of a vaccinia virus protein A40R prevents A40R proteins
from self-polymerization and aggregation in vivo [15]. We
postulated that SUMO modification might be a common
mechanism for virus proteins to retain their solubility or
to prevent improper aggregation before virus assembly
[9]. We believe this hypothesis can be empirically tested
by SUMO fusion protein approach, because several
sumoylated proteins have been mimic in vivo by fusing a
SUMO moiety at their N- or C-terminal ends [16-18].
In this report, we first simultaneously expressed SUMO
fusion proteins of three FMDV capsid proteins (i.e., VP0,
VP1 and VP3) in E. coli. These three fusion proteins form
a ternary complex. This protein complex was then sub-
jected to cleavage with a home-made SUMO protease to
yield a VP0-VP1-VP3 complex. Finally, we showed by EM
imaging analysis that the VP0-VP1-VP3 complexes were
able to assemble into VLPs in vitro.
Materials and methods
Plasmid constructions and protein production
An improved SUMO fusion protein expression system was
carried out as described before [9]. This system uses an
expression vector with PT7lac promoter and TetT7 termina-
tor for expressing SUMO fusion proteins. This vector is
referred here as pHD-Ampr, as it carries an ampicillin
resistant gene (Ampr). In brief, the cDNA encoding any
target protein X is amplified by sticky-end polymerase
chain reaction (PCR), then subcloned into SUMO fusion
protein vectors using two universal cloning sites, SfoI at
the 5' end and XhoI at the 3' end. The resulting expression
vector allows one to express a His6-Smt3-X fusion protein
that can be affinity purified on Ni2+-resins. The purified
fusion protein is then subjected to proteolytic digestion
with a home-made SUMO protease, His6-Ulp1403–621-
His6. The resulting product X is authentic, because its
amino acid sequence is identical to that encoded by the
cDNA. We reported before that a pHD-Ampr-VP3 vector
was successfully applied to produce water-soluble virus
capsid authentic FMDV VP3 protein [9]. To simultane-
ously express three SUMO fusion proteins in the same E.
coli cell, we first constructed a pHD-Kanr vector by replac-
ing Ampr of the pHD-Ampr vector with a kanamycin resist-
ant gene (Kanr). We then constructed pHD-Kanr-VP0 and
pHD-Kanr-VP1 vectors for expressing His6-Smt3-VP0 and
His6-Smt3-VP1 fusion proteins, respectively (Fig. 1A). A
DNA fragment containing PT7lac, His6-Smt3-VP0 and TetT7
was PCR amplified from the pHD-Kanr-VP0 vector, and
then subcloned into pHD-Ampr-VP3 vector to generate a
dual fusion protein expression vector, pHD-Ampr-VP0-
VP3 (Fig. 1A). Both pHD-Ampr-VP0-VP3 and pHD-Kanr-
VP1 vectors were transformed into BL21(DE3)-RIL E. coli
cells (Stratagen, USA), and selected by ampicillin and kan-
amycin resistance. Expression, purification and proteo-
lytic cleavage of His6-Smt3 fusion proteins were carried
out as described before [9].
Gel filtration
Gel filtration was performed by high-pressure liquid chro-
matography with a HiLoad 16/60 Superdex sizing column
(GE Healthcare) and ran at a flow rate of 1.0 ml/min. The
elution profile was followed by a continuous assay of the
optical density at 280 nm. Commercially supplied molec-
ular mass standards (including thyroglobulin, ferritin, cat-
alase, bovine serum albumin, ovalbumin and lysozyme)
were used to calibrate this column. The average elution
position, Kav, was computed by the equation Kav = (Ve -
V0)/(Vt - V0), where Ve and Vt represent elution volumes
for the molecular mass standards and DTT, respectively.Journal of Biomedical Science 2009, 16:69 http://www.jbiomedsci.com/content/16/1/69
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Production of water-soluble FMDV capsid protein complexes Figure 1
Production of water-soluble FMDV capsid protein complexes. (A) Dual SUMO fusion protein expression vectors for 
simultaneous expression of His6-Smt3-VP0, His6-Smt3-VP1 and His6-Smt3-VP3. The two vectors were transformed into 
BL21(DE3)-RIL E. coli cells, and selected by ampicillin (Ampr) and kanamycin resistance (Kanr). (B) SDS-PAGE of the purified 
capsid protein complexes without (left lane) or with (right lane) Ulp1 protease treatment. (C) Gel filtration. Purified capsid 
protein complexes were layered onto a size exclusion column (HiLoad 16/60 Superdex, GE Healthcare), and eluted at 1.0 ml/
min. The elution volume is indicated. Values shown here are the established MWtheo. of commercial globular protein standards, 
and the computed MWapp. of capsid protein complexes from the plot.Journal of Biomedical Science 2009, 16:69 http://www.jbiomedsci.com/content/16/1/69
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V0, the void volume, was determined by blue dextran
2000 (GE, Healthcare).
Electron microscopy
A droplet (4 μl) of purified protein complex was placed
for 1 min at room temperature on a copper grid (300
mesh, Pelco, USA) coated with fresh carbon. The excess
buffer was then carefully blotted away from the edge of
the grid with Whatman #1 filter paper (Whatman Inc.,
USA). After staining for 4 min with 2.5% uranyl acetate,
excess liquid was removed and the samples were air dried
at room temperature. Bio-transmission electron micros-
copy (EM) was performed with a Tecnai G2 Spirit Bio
TWIN (FEI Co., Netherlands) using an acceleration volt-
age of 120 kV. Images were recorded with a slowscan CCD
camera (Gatan MultiScan 600) at a resolution of at least
1024 × 1024 pixels.
Results
Three SUMO fusion proteins (His6-Smt3-VP0, His6-Smt3-
VP1 and His6-Smt3-VP3) were simultaneously expressed
in the same E. coli host cell (Fig. 1A; see Experimental pro-
cedures). Their theoretical molecular weights (MWtheo.)
are 45,175 Da, 37,057 Da and 37,245 Da, respectively.
These three SUMO fusion proteins were all strongly
induced by isopropyl β-D-thiogalactoside and were water-
soluble. Extracts containing coexpressed SUMO fusion
proteins were purified on a Ni2+-resin that selectively
retains His6-tagged polypeptides. Upon examination by
SDS-PAGE stained with Coomassie Blue, the eluates pre-
dominately contained a protein triplet with identical
staining signals (Figure 1B, left lane). The size of the puri-
fied fusion proteins was examined by gel filtration, by
comparison with globular protein standards. The purified
proteins eluted from a size exclusion column at an elution
volume expected for a globular protein with apparent MW
(MWapp.) of 112 kDa (Figure 1C), very close to the
MWtheo. (119,468 Da) of a 1:1:1 ternary protein complex
of these three SUMO fusion proteins. This ternary com-
plex is not due to interactions between His6-Smt3 moie-
ties on these fusion proteins. After His6-Smt3 moieties
were cleaved off from the fusion proteins with SUMO pro-
tease, His6-Smt3 alone existed as monomers in solution
(data not shown). We also found that the His6-Smt3-VP1
fusion protein became water-soluble only when it was
expressed together with both His6-Smt3-VP0 and His6-
Smt3-VP3 in the same E. coli host cell (data not shown).
Therefore, this ternary complex likely contains one copy
of each of these three SUMO fusion proteins. Since the
protomer of the FMDV envelope also contains one copy
of each of VP0, VP1 and VP3 [1], our results suggest that
the purified fusion proteins are structurally similar to the
authentic virus capsid proteins.
The purified SUMO fusion protein complexes were then
treated with SUMO protease to remove the His6-Smt3
moieties. The cleavage products contained three water-
soluble polypeptides with MWapp. ~32 kDa (VP0), 29 kDa
(VP3) and 26 kDa (VP1), respectively (Figure 1B, right
lane). Edman degradation was then performed to confirm
that the N-termini of these three polypeptides were iden-
tical to the expected amino acid sequences of authentic
VP0, VP1 and VP3 proteins (data not shown). The MWtheo.
and isoelectric points (pI) of these polypeptides are 31747
Da (pI = 5.55), 23639 Da (pI = 9.66) and 23,815 Da (pI =
4.87), respectively. Moreover, these polypeptides
migrated together in a size exclusion gel filtration column,
and eluted at an elution volume expected for a globular
protein with MWapp. ~50 kDa (Figure 1C), indicating that
they form a 1:1:1 non-globular complex (MWtheo.  =
79,201 Da). The final yield of purified VP0-VP1-VP3 ter-
nary complexes is ~5 mg of protein per liter of cell culture.
It is unlikely that this eluted protein peak contains a mix-
ture of dimmers of each individual protein since His6-
Smt3-VP1 became water-soluble only when it was co-
expressed with both His6-Smt3-VP0 and His6-Smt3-VP3
in the same E. coli host cell. Finally, we found that the
purified VP0-VP1-VP3 ternary complexes could assemble
into large protein aggregates (Figure 2) which eluted faster
than thyroglobin (MW ~660 kDa) in the same size exclu-
sion gel filtration column described in Figure 1C. We then
used transmission electron microscopy to examine the
extent of VLP assembly by these ternary protein complexes
(Fig. 3A–C). Indeed, the VP0-VP1-VP3 complexes formed
round VLP aggregates with diameters ~25 nm. A previous
EM study had revealed that the size of authentic FMDV is
27 nm [1]. By contrast, the ternary complexes of His6-
Smt3-VP0, His6-Smt3-VP1 and His6-Smt3-VP3 formed
hardly any round-shaped VLP (Fig. 3D). Taken together,
we conclude that VP0-VP1-VP3 complexes are capable of
forming VLP in vitro, and that the presence of His6-Smt3
fusion components impedes VLP assembly between
SUMO fusion proteins.
Discussion
In this study, we have demonstrated for the first time the
production of FMDV VLPs in E. coli. A bacterial expression
system using E. coli has numerous advantages over other
expression systems, including ease of handling, much
lower cost and efficient generation time. The FMDV VLPs
so produced may be applicable for prophylactic vaccina-
tion or as molecular tools in nanobiotechnology [4].
Finally, viruses within the Picornaviridae  family show
much conservation in capsid protein composition and
structural organization, including hepatitis A virus (HAV),
the polio virus and the EV71 hand-foot-and-mouth dis-
ease virus. Recently, we also have successfully applied the
same approach to produce soluble VP0-VP1-VP3 ternary
complexes of HAV (CD Lee and Wang TF, unpublishedJournal of Biomedical Science 2009, 16:69 http://www.jbiomedsci.com/content/16/1/69
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data). Therefore, our method likely will be applicable to
produce capsid protein complexes or VLPs of other Picor-
naviridae viruses.
Our results also indicated that addition of SUMO moie-
ties could prevent aggregation of FMDV capsid proteins.
After the SUMO moieties were removed from these capsid
proteins, they were able to form VLPs with size and shape
resembling those of native FMDV viruses. These results are
consistent with the hypothesis that SUMO modification
not only increases the solubility of capsid proteins but
also prevents improper aggregation before virus assembly.
It is of interest to further investigate if SUMO modifica-
tions indeed control virus assembly in vivo. Finally, our
study here reveals a simple way to control FMDV VLP
assembly in vitro, it may be useful in nanoparticle biotech-
nology.
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Purified VP0-VP1-VP3 capsid protein complexes spontaneously formed large protein aggregates Figure 2
Purified VP0-VP1-VP3 capsid protein complexes spontaneously formed large protein aggregates. (A) Gel filtra-
tion. Purified capsid protein complexes (Fig. 1C) were reloaded onto a size exclusion column (HiLoad 16/60 Superdex, GE 
Healthcare), and eluted at 1.0 ml/min. The elution volume is indicated. A significant portion of VP0-VP1-VP3 capsid protein 
complexes formed large protein aggregates. (B) SDS-PAGE of VP0-VP1-VP3 protein complexes from indicated fractions.Journal of Biomedical Science 2009, 16:69 http://www.jbiomedsci.com/content/16/1/69
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The VP0-VP1-VP3 protein complexes form round VPLs in vitro Figure 3
The VP0-VP1-VP3 protein complexes form round VPLs in vitro. Negative-staining electron microscopy images of the 
purified VP0-VP1-VP3 proteins (A-C) and the His6-Smt3-VP0/His6-Smt3-VP1/His6-Smt3-VP3 ternary complexes (D). Scale bars 
(in black) are 50, 100 or 200 nm as indicated.Publish with BioMed Central    and   every 
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